```html

Wasting (Cachexia)

What is Wasting (cachexia)?

Wasting, medically known as cachexia, is a complex metabolic syndrome characterized by severe loss of body weight, muscle mass, and fat tissue. Unlike simple starvation, cachexia occurs despite adequate or even increased caloric intake and is driven by an underlying disease that produces inflammatory mediators, hormonal changes, and altered protein metabolism. It most commonly affects people with advanced chronic illnesses such as cancer, heart failure, chronic kidney disease, and chronic obstructive pulmonary disease (COPD).

Key features of cachexia include:

• Unintentional weight loss of >5% of usual body weight over 12 months or less.
• Loss of skeletal muscle (sarcopenia) that cannot be fully reversed by conventional nutrition support.
• Reduced appetite (anorexia), fatigue, and a generalized feeling of weakness.
• Systemic inflammation reflected by elevated markers such as C‑reactive protein (CRP) and interleukin‑6 (IL‑6).

Cachexia is a life‑threatening condition that worsens prognosis, reduces quality of life, and often complicates the management of the underlying disease. Early recognition and a multidisciplinary treatment approach are essential.

Common Causes

Cachexia is not a disease itself but a manifestation of several serious medical conditions. The most frequent causes include:

• Cancer – especially pancreatic, gastric, lung, and head‑and‑neck tumors.
• Chronic heart failure – advanced New York Heart Association (NYHA) class III‑IV.
• Chronic obstructive pulmonary disease (COPD) – severe airflow limitation with frequent exacerbations.
• Chronic kidney disease (CKD) – end‑stage renal disease on dialysis.
• HIV/AIDS – persistent viral replication and opportunistic infections.
• Rheumatoid arthritis and other systemic inflammatory disorders – high cytokine load.
• Severe liver disease (cirrhosis) – portal hypertension and malabsorption.
• Neuromuscular diseases – amyotrophic lateral sclerosis (ALS), muscular dystrophy.
• Sepsis and chronic infections – prolonged inflammatory response.
• Advanced diabetes mellitus – when complicated by renal failure or severe malnutrition.

Associated Symptoms

Patients with cachexia often experience a constellation of symptoms that reflect both the metabolic derangement and the underlying illness:

• Loss of appetite (anorexia) or early satiety.
• Fatigue, weakness, and reduced exercise tolerance.
• Edema (especially in heart failure or kidney disease).
• Dry or thinning hair, brittle nails.
• Dry skin, pruritus.
• Depression or anxiety related to body‑image changes.
• Impaired immune function – leading to frequent infections.
• Dyspnea (shortness of breath) in pulmonary disease.
• Abdominal discomfort or early fullness from ascites (in liver disease).

When to See a Doctor

Because wasting can rapidly progress and influence treatment outcomes, seek medical attention promptly if you notice:

• Unexplained weight loss of ≥5% of your usual body weight within 6–12 months.
• Noticeable loss of muscle bulk (e.g., arms, thighs) even if overall weight seems stable.
• Persistent loss of appetite that lasts more than a few weeks.
• New or worsening fatigue that limits daily activities.
• Swelling in the legs, abdomen, or around the eyes.
• Difficulty swallowing (dysphagia) or frequent nausea/vomiting.
• Any rapid change in health status in the context of a known chronic disease (cancer, heart failure, etc.).

Early evaluation can identify reversible contributors (e.g., medication side‑effects, depression) and allow initiation of targeted therapies.

Diagnosis

Diagnosing cachexia requires a systematic approach that combines clinical assessment, laboratory testing, and sometimes imaging.

1. Clinical Evaluation

• Detailed history – rate of weight loss, dietary intake, presence of underlying disease, medication review.
• Physical examination – assessment of muscle wasting (e.g., mid‑arm circumference), edema, and signs of the primary disease.

2. Anthropometric Measurements

• Body weight and body mass index (BMI).
• Unintentional weight loss percentage.
• Lean body mass measured by bioelectrical impedance analysis (BIA) or dual‑energy X‑ray absorptiometry (DXA).

3. Laboratory Tests

• Complete blood count (CBC) – anemia, infection.
• Comprehensive metabolic panel – albumin, pre‑albumin, electrolytes.
• Inflammatory markers – C‑reactive protein (CRP), erythrocyte sedimentation rate (ESR), IL‑6.
• Hormonal profile – cortisol, thyroid function.
• Specific disease markers – tumor markers, natriuretic peptides (BNP) for heart failure.

4. Imaging & Functional Tests

• CT or MRI of the abdomen/pelvis – can quantify muscle cross‑sectional area (gold standard for sarcopenia).
• Echocardiogram – assesses cardiac function if heart failure is suspected.
• Pulmonary function tests – for COPD‑related wasting.

5. Diagnostic Criteria

According to the International Consensus (Fearon et al., 2011), cachexia is present when at least three of the following are met:

1. Weight loss >5% over 12 months (or >2% in individuals with BMI < 20 kg/m²).
2. Reduced muscle strength (hand‑grip < 30 kg men, < 20 kg women).
3. Fatigue, anorexia, or low intake.
4. Laboratory evidence of inflammation (CRP > 5 mg/L) or low albumin (< 3.2 g/dL).

Treatment Options

Treatment must be individualized, addressing both the underlying disease and the metabolic abnormalities of cachexia. A multidisciplinary team—physicians, dietitians, physiotherapists, and mental‑health providers—optimizes outcomes.

1. Treat the Underlying Condition

• Effective oncologic therapy (surgery, chemotherapy, immunotherapy) can halt tumor‑driven catabolism.
• Optimized heart failure regimens (ACE inhibitors, beta‑blockers, diuretics) reduce neurohormonal stress.
• Antiretroviral therapy for HIV, disease‑modifying antirheumatic drugs for RA, etc.

2. Nutritional Interventions

• Caloric supplementation – high‑energy oral nutrition supplements (e.g., 1.5 kcal/mL) taken 2–3 times daily.
• Protein enrichment – aim for 1.2–1.5 g protein/kg body weight per day.
• Enteral feeding (nasogastric or PEG tube) if oral intake remains insufficient.
• Parenteral nutrition reserved for severe malabsorption or when enteral feeding is contraindicated.

3. Pharmacologic Therapies

• Appetite stimulants – megestrol acetate, ghrelin mimetics (e.g., anamorelin – approved in Japan).
• Anti‑inflammatory agents – selective NSAIDs or cytokine‑targeted drugs (e.g., anti‑IL‑6 antibodies) under investigation.
• Anabolic agents – selective androgen receptor modulators (SARMs) and low‑dose testosterone may help preserve muscle.
• Omega‑3 fatty acids – EPA‑rich supplements have modest benefits on weight and inflammatory markers.
• Multimodal regimens – combination of nutrition, exercise, and pharmacology provides the best results (Cleveland Clinic, 2022).

4. Exercise and Physical Therapy

• Resistance training 2–3 times per week to stimulate muscle protein synthesis.
• Aerobic activity (e.g., walking, stationary cycling) improves cardiovascular fitness and appetite.
• Physical therapy tailored to functional status—important for preventing falls and preserving independence.

5. Psychological Support

• Counselling or cognitive‑behavioral therapy to address depression, anxiety, and body‑image concerns.
• Support groups for patients and caregivers.

6. Palliative Care

When cachexia occurs in end‑stage disease, integrating palliative care focuses on symptom relief, nutritional comfort, and quality‑of‑life goals.

Prevention Tips

While cachexia cannot always be prevented, especially when linked to aggressive cancers, several proactive steps can reduce risk or mitigate severity:

• Early disease management – adhere to treatment plans for chronic illnesses (e.g., heart failure meds, HIV therapy).
• Regular nutritional screening – annual weight and appetite assessments for high‑risk patients.
• Balanced diet – include lean protein, healthy fats, whole grains, and plenty of fruits/vegetables.
• Maintain physical activity – even light resistance exercises preserve muscle mass.
• Control inflammation – manage infections promptly and avoid smoking or excessive alcohol.
• Vaccinations – flu and pneumococcal vaccines reduce respiratory infections that can trigger catabolic states.
• Monitor medication side‑effects – some drugs (e.g., certain chemotherapies) suppress appetite; discuss alternatives with your physician.
• Psychological wellbeing – treat depression early, as it can worsen appetite loss.

Emergency Warning Signs

If you or a loved one experiences any of the following, seek immediate medical attention (call 911 or go to the nearest emergency department):

• Rapid weight loss (>10% in < 1 month) accompanied by severe vomiting, diarrhea, or inability to keep any food down.
• Sudden onset of intense abdominal pain with swelling, indicating possible bowel obstruction or perforation.
• Severe shortness of breath at rest, especially if associated with chest pain or swelling in the legs (possible pulmonary embolism or acute heart failure).
• Loss of consciousness, severe dizziness, or new‑onset confusion.
• Uncontrolled bleeding or signs of infection (high fever > 38.5 °C, chills, rapid heartbeat) that do not improve with standard care.

Early detection and a coordinated treatment plan can significantly improve outcomes for people dealing with wasting (cachexia). If you notice unexplained weight loss or related symptoms, contact your healthcare provider promptly.

---

References: 1. Fearon K, et al. Definition and Classification of Cancer Cachexia: An International Consensus. *Lancet Oncology*. 2011;12(5):489‑495. 2. Mayo Clinic. Cachexia. https://www.mayoclinic.org/diseases-conditions/cachexia/symptoms-causes (accessed May 2026). 3. National Institute on Aging. Sarcopenia and Age‑Related Muscle Loss. https://www.nia.nih.gov/health/sarcopenia (accessed May 2026). 4. Cleveland Clinic. Cachexia: Management Strategies. https://my.clevelandclinic.org/health/diseases/15936-cachexia (accessed May 2026). 5. World Health Organization. WHO Guidelines on Nutrition for Adults with Chronic Disease. 2022. 6. CDC. Chronic Kidney Disease in the United States, 2023 Report. https://www.cdc.gov/kidneydisease/publications.html (accessed May 2026). ```